312 related articles for article (PubMed ID: 17147908)
1. Prevention of VZV infection in immunosuppressed patients using antiviral agents.
Boeckh M
Herpes; 2006 Nov; 13(3):60-5. PubMed ID: 17147908
[TBL] [Abstract][Full Text] [Related]
2. Varicella-zoster infection after allogeneic bone marrow transplantation: incidence, risk factors and prevention with low-dose aciclovir and ganciclovir.
Steer CB; Szer J; Sasadeusz J; Matthews JP; Beresford JA; Grigg A
Bone Marrow Transplant; 2000 Mar; 25(6):657-64. PubMed ID: 10734301
[TBL] [Abstract][Full Text] [Related]
3. Long-term low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation.
Kanda Y; Mineishi S; Saito T; Saito A; Yamada S; Ohnishi M; Chizuka A; Niiya H; Suenaga K; Nakai K; Takeuchi T; Makimoto A; Tanosaki R; Kami M; Tanaka Y; Fujita S; Watanabe T; Kobayashi Y; Tobinai K; Takaue Y
Bone Marrow Transplant; 2001 Oct; 28(7):689-92. PubMed ID: 11704792
[TBL] [Abstract][Full Text] [Related]
4. Impact of the duration of antiviral prophylaxis on rates of varicella-zoster virus reactivation disease in autologous hematopoietic cell transplantation recipients.
Truong Q; Veltri L; Kanate AS; Hu Y; Craig M; Hamadani M; Cumpston A
Ann Hematol; 2014 Apr; 93(4):677-82. PubMed ID: 24097085
[TBL] [Abstract][Full Text] [Related]
5. Long-term ultra-low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation.
Asano-Mori Y; Kanda Y; Oshima K; Kako S; Shinohara A; Nakasone H; Sato H; Watanabe T; Hosoya N; Izutsu K; Asai T; Hangaishi A; Motokura T; Chiba S; Kurokawa M
Am J Hematol; 2008 Jun; 83(6):472-6. PubMed ID: 18266207
[TBL] [Abstract][Full Text] [Related]
6. Clinical features and risk factors for developing varicella zoster virus dissemination following hematopoietic stem cell transplantation.
Umezawa Y; Kakihana K; Oshikawa G; Kobayashi T; Doki N; Sakamaki H; Ohashi K
Transpl Infect Dis; 2014 Apr; 16(2):195-202. PubMed ID: 24438510
[TBL] [Abstract][Full Text] [Related]
7. The effect of low-dose aciclovir on reactivation of varicella zoster virus after allogeneic haemopoietic stem cell transplantation.
Thomson KJ; Hart DP; Banerjee L; Ward KN; Peggs KS; Mackinnon S
Bone Marrow Transplant; 2005 Jun; 35(11):1065-9. PubMed ID: 15806119
[TBL] [Abstract][Full Text] [Related]
8. Daily 500 mg valacyclovir is effective for prevention of Varicella zoster virus reactivation in patients with multiple myeloma treated with bortezomib.
Fukushima T; Sato T; Nakamura T; Iwao H; Nakajima A; Miki M; Sakai T; Kawanami T; Sawaki T; Fujita Y; Tanaka M; Masaki Y; Okazaki T; Nakajima H; Motoo Y; Umehara H
Anticancer Res; 2012 Dec; 32(12):5437-40. PubMed ID: 23225448
[TBL] [Abstract][Full Text] [Related]
9. Two cases of varicella zoster virus meningitis found in pediatric patients after bone marrow transplantation despite valaciclovir prophylaxis and without skin lesions.
Lévêque N; Galambrun C; Najioullah F; Bleyzac N; Pages MP; Bertrand Y
J Med Virol; 2006 Apr; 78(4):514-6. PubMed ID: 16482541
[TBL] [Abstract][Full Text] [Related]
10. One-year acyclovir prophylaxis for preventing varicella-zoster virus disease after hematopoietic cell transplantation: no evidence of rebound varicella-zoster virus disease after drug discontinuation.
Erard V; Guthrie KA; Varley C; Heugel J; Wald A; Flowers ME; Corey L; Boeckh M
Blood; 2007 Oct; 110(8):3071-7. PubMed ID: 17515400
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of acyclovir prophylaxis against varicella zoster virus disease after allogeneic hematopoietic cell transplantation: A systematic review and meta-analysis.
Wada-Shimosato Y; Tanoshima R; Hiratoko K; Takeuchi M; Tsujimoto SI; Shiba N; Ito S; Yamanaka T; Ito S
Transpl Infect Dis; 2019 Jun; 21(3):e13061. PubMed ID: 30756465
[TBL] [Abstract][Full Text] [Related]
12. Postexposure prophylaxis against varicella zoster virus infection among hematopoietic stem cell transplant recipients.
Weinstock DM; Boeckh M; Sepkowitz KA
Biol Blood Marrow Transplant; 2006 Oct; 12(10):1096-7. PubMed ID: 17084374
[No Abstract] [Full Text] [Related]
13. Clinicopathologic understanding and control of varicella-zoster virus infection.
Asano Y
Vaccine; 2008 Nov; 26(50):6487-90. PubMed ID: 18694794
[TBL] [Abstract][Full Text] [Related]
14. Prophylactic role of long-term ultra-low-dose acyclovir for varicella zoster virus disease after allogeneic hematopoietic stem cell transplantation.
Kawamura K; Wada H; Yamasaki R; Ishihara Y; Sakamoto K; Ashizawa M; Sato M; Machishima T; Terasako K; Kimura S; Kikuchi M; Nakasone H; Yamazaki R; Kanda J; Kako S; Tanihara A; Nishida J; Kanda Y
Int J Infect Dis; 2014 Feb; 19():26-32. PubMed ID: 24211377
[TBL] [Abstract][Full Text] [Related]
15. Varicella-zoster virus infections in the immunocompromised host. Natural history and treatment.
Balfour HH
Scand J Infect Dis Suppl; 1991; 80():69-74. PubMed ID: 1666447
[TBL] [Abstract][Full Text] [Related]
16. Advances in the treatment of varicella-zoster virus infections.
Andrei G; Snoeck R
Adv Pharmacol; 2013; 67():107-68. PubMed ID: 23886000
[TBL] [Abstract][Full Text] [Related]
17. Antiviral therapy for varicella and herpes zoster.
Arvin AM
Semin Pediatr Infect Dis; 2002 Jan; 13(1):12-21. PubMed ID: 12118839
[TBL] [Abstract][Full Text] [Related]
18. One-year low-dose valacyclovir as prophylaxis for varicella zoster virus disease after allogeneic hematopoietic stem cell transplantation. A prospective study of the Japan Hematology and Oncology Clinical Study Group.
Oshima K; Takahashi T; Mori T; Matsuyama T; Usuki K; Asano-Mori Y; Nakahara F; Okamoto S; Kurokawa M; Kanda Y
Transpl Infect Dis; 2010 Oct; 12(5):421-7. PubMed ID: 20626711
[TBL] [Abstract][Full Text] [Related]
19. Incidence, risk factors, and implemented prophylaxis of varicella zoster virus infection, including complicated varicella zoster virus and herpes simplex virus infections, in lenalidomide-treated multiple myeloma patients.
König C; Kleber M; Reinhardt H; Knop S; Wäsch R; Engelhardt M
Ann Hematol; 2014 Mar; 93(3):479-84. PubMed ID: 24318541
[TBL] [Abstract][Full Text] [Related]
20. Emerging drugs for varicella-zoster virus infections.
Andrei G; Snoeck R
Expert Opin Emerg Drugs; 2011 Sep; 16(3):507-35. PubMed ID: 21699441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
